Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs

Journal of Pharmaceutical Sciences

Volumn 99, Issue 2, 2010, Pages 621-625

  Kortejarvi H ^a,b   Shawahna, R ^b,c   Koski, A ^a   Malkki, J ^a   Ojala, K ^a   Yliperttula, M ^b  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

Author keywords

Absorption; Bioequivalence; Biopharmaceutics classification system (BCS); Dissolution rate; Solubility

Indexed keywords

AMILORIDE; AMITRIPTYLINE; CHLOROQUINE; CHLORPHENIRAMINE; CLOMIPRAMINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIAZEPAM; DIETHYLCARBAMAZINE; ETHINYLESTRADIOL; ETHOSUXIMIDE; FLUCONAZOLE; ISONIAZID; LEVAMISOLE; LEVODOPA; LEVONORGESTREL; LEVOTHYROXINE; NICOTINAMIDE; NORETHISTERONE; PHENOBARBITAL; PREDNISOLONE; PROGUANIL; PROPRANOLOL; PYRAZINAMIDE; PYRIDOXINE; QUININE; SALBUTAMOL; STAVUDINE; THEOPHYLLINE; UNINDEXED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; DISSOLUTION; DRUG ABSORPTION; DRUG ELIMINATION; DRUG HALF LIFE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR MODEL;

EID: 74049120114     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21879     Document Type: Article

References (11)

1. European Medicines Agency (EMEA) 2008. Committee for Medicinal Products for human use (CHMP). Draft Guideline on the Investigation of Bioequivalence.
2. Guidance for Industry. U.S. Department of Health and Human Services and Drug Administration Center for Drug Evaluation and Research (CDER), 2000. Guidance for Industry: Waiver of In Vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Rockville, MD: Food and Drug Administration.
3. European Medicines Agency (EMEA) 2002. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the Investigation of Bioavailability and Bioequivalence.
4. World Health Organization (WHO) 2006. Multisource (generic) pharmaceutical products: Guidelines on registration requirements to establish interchangeability. Annex 7. WHO technical report series No. 937.
5. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58:265-278.
6. Yu LX, Crison JR, Amidon GL. 1996. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 140: 111-118.
7. Kortejärvi H, Urtti A, Yliperttula M. 2007. Pharmacokinetic simulation of biowaiver criteria: The effects of gastric emptying, dissolution and absorption and elimination rates. Eur J Pharm Sci 30:155-166.
8. Linnankoski J, Mäkelä JM, Ranta V-P, Urtti A, Yliperttula M. 2006. Computational prediction of oral drug absorption based on absorption rate constants in humans. J Med Chem 49:3674-3681.
9. Obach RS, Lombardo F, Waters NJ. 2008. Trend analysis of a database of intravenous pharmacokinetic parameters in human for 670 drug compounds. Drug Metab Dispos 36:1385-1405.
10. Moore JW, Flanner HH. 1996. Mathematical comparison of dissolution profiles. Pharm Tech 20: 64-74.
11. Kaus LC, Gillespie WR, Hussain AS, Amidon GL. 1999. The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharm Res 16:272-280.